Letter/Communication
The HA-1A Monoclonal Antibody for Gram-Negative Sepsis
The New England journal of medicine, Vol.325(4), pp.279-283
07/25/1991
DOI: 10.1056/NEJM199107253250411
PMID: 2057029
Abstract
To the Editor:
Ziegler and collaborators (Feb. 14 issue)
1
recently reported on an impressive reduction in 28-day mortality, from 49 percent to 30 percent, in a subgroup of patients who had bacteremia due to gram-negative bacilli. The patients were treated with human anti—lipid A monoclonal antibody early in the course after the onset of symptoms. Patients with sepsis or bacteremia caused by microorganisms other than gram-negative bacilli received no measurable benefit. These results prompted the investigators to recommend the therapy as routine treatment for patients with clinical signs of bacteremia, provided that a gram-negative organism was suspected as the cause. . . .
Details
- Title: Subtitle
- The HA-1A Monoclonal Antibody for Gram-Negative Sepsis
- Creators
- Gregory A Schmidt - University of Chicago
- Resource Type
- Letter/Communication
- Publication Details
- The New England journal of medicine, Vol.325(4), pp.279-283
- Publisher
- Massachusetts Medical Society
- DOI
- 10.1056/NEJM199107253250411
- PMID
- 2057029
- ISSN
- 0028-4793
- eISSN
- 1533-4406
- Language
- English
- Date published
- 07/25/1991
- Academic Unit
- Pulmonary, Critical Care, and Occupational Medicine; Internal Medicine
- Record Identifier
- 9984359765902771
Metrics
8 Record Views